231 related articles for article (PubMed ID: 33310050)
1. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
2. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
3. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
4. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
6. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
7. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
8. Kinesin-5: cross-bridging mechanism to targeted clinical therapy.
Wojcik EJ; Buckley RS; Richard J; Liu L; Huckaba TM; Kim S
Gene; 2013 Dec; 531(2):133-49. PubMed ID: 23954229
[TBL] [Abstract][Full Text] [Related]
9. New chemical tools for investigating human mitotic kinesin Eg5.
Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L
Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
Peters T; Lindenmaier H; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
[TBL] [Abstract][Full Text] [Related]
11. Monastrol inhibition of the mitotic kinesin Eg5.
Cochran JC; Gatial JE; Kapoor TM; Gilbert SP
J Biol Chem; 2005 Apr; 280(13):12658-67. PubMed ID: 15665380
[TBL] [Abstract][Full Text] [Related]
12. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
13. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
14. A structural model for monastrol inhibition of dimeric kinesin Eg5.
Krzysiak TC; Wendt T; Sproul LR; Tittmann P; Gross H; Gilbert SP; Hoenger A
EMBO J; 2006 May; 25(10):2263-73. PubMed ID: 16642039
[TBL] [Abstract][Full Text] [Related]
15. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
17. Eg5 Inhibitors Have Contrasting Effects on Microtubule Stability and Metaphase Spindle Integrity.
Chen GY; Kang YJ; Gayek AS; Youyen W; Tüzel E; Ohi R; Hancock WO
ACS Chem Biol; 2017 Apr; 12(4):1038-1046. PubMed ID: 28165699
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
[TBL] [Abstract][Full Text] [Related]
19. Identification of MAC1: A Small Molecule That Rescues Spindle Bipolarity in Monastrol-Treated Cells.
Al-Obaidi N; Mitchison TJ; Crews CM; Mayer TU
ACS Chem Biol; 2016 Jun; 11(6):1544-51. PubMed ID: 27121275
[TBL] [Abstract][Full Text] [Related]
20. KIF15 nanomechanics and kinesin inhibitors, with implications for cancer chemotherapeutics.
Milic B; Chakraborty A; Han K; Bassik MC; Block SM
Proc Natl Acad Sci U S A; 2018 May; 115(20):E4613-E4622. PubMed ID: 29703754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
